ArticleInfection and immunity2012
Evaluation of Salmonella enterica type III secretion system effector proteins as carriers for heterologous vaccine antigens.
Article in Infection and immunity, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 45 citations in OpenAlex.
- Engineered bacteria launch and control an oncolytic virus.Nature biomedical engineering · 2026Article
- Control of antigen presentation on MHC-I by a bacterial secretion system.bioRxiv : the preprint server for biology · 2025Article
- Enoxacin adversely affects Salmonella enterica virulence and host pathogenesis through interference with type III secretion system type II (T3SS-II) and disruption of translocation of Salmonella Pathogenicity Island-2 (SPI2) effectors.Journal of microbiology (Seoul, Korea) · 2025Article
- Sulforaphane Is Not Only a Food Supplement: It Diminishes the Intracellular Survival and Colonization ofACS omega · 2025Article
- Genetic engineering ofEcoSal Plus · 2024Review
- Advancing vaccine technology through the manipulation of pathogenic and commensal bacteria.Materials today. Bio · 2024Review
- Controlling of Bacterial Virulence: Evaluation of Anti-Virulence Activities of Prazosin againstAntibiotics (Basel, Switzerland) · 2022Article
- Silencing ofMicroorganisms · 2022Article
- Terazosin Interferes with Quorum Sensing and Type Three Secretion System and Diminishes the Bacterial Espionage to Mitigate theAntibiotics (Basel, Switzerland) · 2022Article
- Alteration ofMicroorganisms · 2021Article
- Advances in the development of Salmonella-based vaccine strategies for protection against Salmonellosis in humans.Journal of applied microbiology · 2021Review
- Oral immunization of rat with chromosomal expression LipL32 in attenuatedClinical and experimental vaccine research · 2021Article
- Pathogenic signature of invasive non-typhoidalHuman vaccines & immunotherapeutics · 2020Review
- A LivemSphere · 2019Article
- Rationale redesign of type III secretion systems: toward the development of non-pathogenic E. coli for in vivo delivery of therapeutic payloads.Current opinion in microbiology · 2018Review
- Lessons Learned from Protective Immune Responses to Optimize Vaccines against Cryptosporidiosis.Pathogens (Basel, Switzerland) · 2017Review
- Intracellular delivery of biologic therapeutics by bacterial secretion systems.Expert reviews in molecular medicine · 2017Review
- An autotransporter display platform for the development of multivalent recombinant bacterial vector vaccines.Microbial cell factories · 2014Article
- Effective cancer vaccine platform based on attenuated salmonella and a type III secretion system.Cancer research · 2014Article
- Aeromonas salmonicida subsp. salmonicida in the light of its type-three secretion system.Microbial biotechnology · 2014Review
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
Abstract
Live attenuated strains of Salmonella enterica have a high potential as carriers of recombinant vaccines. The type III secretion system (T3SS)-dependent translocation of S. enterica can be deployed for delivery of heterologous antigens to antigen-presenting cells. Here we investigated the efficacy of various effector proteins of the Salmonella pathogenicity island (SPI2)-encoded T3SS for the translocation of model antigens and elicitation of immune responses. The SPI2 T3SS effector proteins SifA, SteC, SseL, SseJ, and SseF share an endosomal membrane-associated subcellular localization after translocation. We observed that all effector proteins could be used to translocate fusion proteins with the model antigens ovalbumin and listeriolysin into the cytosol of host cells. Under in vitro conditions, fusion proteins with SseJ and SteC stimulated T-cell responses that were superior to those triggered by fusion proteins with SseF. However, in mice vaccinated with Salmonella carrier strains, only fusion proteins based on SseJ or SifA elicited potent T-cell responses. These data demonstrate that the selection of an optimal SPI2 effector protein for T3SS-mediated translocation is a critical parameter for the rational design of effective Salmonella-based recombinant vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.